menu
The TIL-based therapies market is projected to be worth over USD 4.3 billion, by 2030, claims Roots Analysis
TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status

Driven bythe potential to confer sustained therapeutic effects and thereby, facilitateprolonged periods of remission, TIL-based therapies have received significantfinancial support, and promising leads are poised to soon achieve blockbusterstatus

 

Roots Analysis has announced the addition of “TIL-based Therapies Market,2021-2030” report to its list ofofferings.

 

Given the frequently reported inadequacies ofconventional cancer therapies and the growing need for personalized medicine,there is a marked surge in the demand for TIL-based therapies. In addition, theclinical success in this domain is likely to draw in investments that willsupport ongoing and anticipated therapy development initiatives.

 

Toorder this 255+ page report, which features 90+ figures and 100+ tables, pleasevisit

https://www.rootsanalysis.com/reports/til-therapies-market.html

 

Key Market Insights

 

Over 80 TIL-based therapies arecurrently under development

Closeto 55% of the aforementioned candidates are being evaluated in clinical stages(phase I/II and above), while more than 20% therapies are in preclinicaland discovery stages. Examples of late-stage clinical candidates includeCCRT+TIL, Lifileucel, LTX-315 and TILs, and IOV-2001 and LN-145.

 

More than 80% pipeline candidates are presently beingdeveloped to target solid tumors

T-cell immunotherapy developers were observed to beprimarily focused on the treatment of different oncological indications. It isworth noting that 17% pipeline candidates are being developed for the treatmentof both hematological and solid tumors.

 

Partnership activitywithin this domain has increased at a CAGR of 45%, between 2011 and 2020

The maximum partnerships related to TIL-based therapieswere inked in the period 2017-2019. Majority of partnership deals signed withinthis domain were R&D agreements (33%), followed by technology licensing(20%) and manufacturing (15%) agreements.

 

Over USD 2 billion has been invested by both private andpublic investors, across 30 instances

It is important to mention that, between 2013 and 2020,majority of the funding amount was raised through other equity financingelements (33%), venture capital rounds (30%) and secondary offerings (20%).

 

This market isanticipated to grow at a CAGR of 60.6%, during the period 2021-2030

Growth in this domain isanticipated to be primarily driven by encouraging clinical trial results andlikely approval of some advanced stage therapy candidates. Further, NorthAmerica (primarily the US) and Europe are expected to capture over 90%of the market share (in terms of sales-based revenues) by 2030.

 

To request a samplecopy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/til-therapies-market.html

 

KeyQuestions Answered

§ What are the prevalent R&D trends related to TIL-basedtherapies?

§  Whoare the leading industry and non-industry players engaged in the development ofTIL-based therapies?

§  Whatchallenges are commonly faced by stakeholders engaged in this domain?

§  Whoare the key investors in this domain?

§  Whoare the key opinion leaders / experts engaged in this upcoming field oftherapeutics?

§  Whichtypes of partnership models are commonly adopted by industry stakeholders?

§  Whichregions are key contract manufacturing hubs for TIL-based therapies?

§  Whichfactors are likely to influence the evolution of this upcoming market?

§ How is the current and future market opportunity likely tobe distributed across key market segments?

 

The USD 4.3+ billion (by 2030) financial opportunity within theTIL-based therapies market has been analyzed across the following segments:

 

§ Target Indication

§  AcuteLymphoblastic Leukemia

§  Melanoma

§  Others

 

§ Key Players

 

§  KeyGeographical Regions 

§  NorthAmerica

§  Europe

§  AsiaPacific

 

The research includes brief profiles, featuring an overviewof the company, its financial information (if available), detailsrelated to its product(s), highlighting type of therapy and current developmentstatus, technology portfolio (if available), recent developments andmanufacturing capabilities. 

§ Cellular Biomedicine Group

§ Iovnace Biotherapeutics

§ Lytix Biopharma

§ Phio Pharmaceuticals

 

For additionaldetails, please visit 

https://www.rootsanalysis.com/reports/til-therapies-market.html oremail sales@rootsanalysis.com

 

You may also beinterested in the following titles:

1.    Global T-Cell Therapies Market (5th Edition): IndustryTrends and Global Forecasts, 2021-2030

2.    CAR-T Cell TherapiesMarket(3rd Edition): Industry Trends and Global Forecasts, 2021-2030

3.    TCR-based TherapiesMarket:Industry Trends and Global Forecasts, 2021-2030

4.    Cell and Gene TherapyCROs Market:Industry Trends and Global Forecasts (2nd Edition), 2021-2030

5.    Gene Therapy Market (4th Edition): IndustryTrends and Global Forecasts, 2020-2030

 

 

About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

RootsAnalysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter- https://twitter.com/RootsAnalysis